Inducible nitric oxide synthase in renal transplantation  by Joles, Jaap A. et al.
Kidney International, Vol. 61 (2002), pp. 872–875
Inducible nitric oxide synthase in renal transplantation
JAAP A. JOLES, INGRID H. VOS, HERMANN-JOSEF GRO¨NE, and TON J. RABELINK
Departments of Nephrology and Hypertension, and Vascular Medicine, University Medical Center, Utrecht, the Netherlands,
and Department of Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany
Inducible nitric oxide synthase in renal transplantation. The meostasis [8]. In hypertension renal iNOS expression can
importance of the endothelial isoform of nitric oxide synthase be increased as a compensatory response to increased
(eNOS) has been well established. Endothelium-derived nitric reactive oxygen species (ROS), as in lead-induced hyper-oxide has been shown to be essential for vascular homeostasis
tension [9], in the spontaneously hypertensive rat (SHR),and modulation of eNOS has thus become a target in preven-
where renal iNOS expression is already up early in lifetion of cardiovascular disease. The role of the inducible form of
nitric oxide synthase (iNOS) in vascular biology, however, is less [10], and in stroke-prone SHR [11].
clear. Classically, iNOS has been regarded as an enzyme that
produces nmolar amounts of the nitric oxide radical, thereby
leading to cellular damage. More recent data, however, have ACUTE REJECTION IN RENAL ALLOGRAFTS
shown that the iNOS can be a superoxide, peroxynitrite as well AND iNOSas a nitric oxide-producing enzyme, while the biological effects
of iNOS probably depend upon the sort of radical species In acute rejection in renal allografts up-regulated
released by the enzyme as well as the anti-oxidant capacity of iNOS expression was associated with infiltrating cells
the cellular microenvironment of the enzyme. This brief review (Vos et al unpublished data). iNOS expression could bediscusses these aspects in relation to renal transplantation.
found also in acute human renal allograft rejection, where
both glomerular and interstitial iNOS expression were in-
creased [12]. iNOS expression in most cell types requiresInducible nitric oxide synthase is constitutively ex-
exposure to inflammatory stimuli such as cytokines andpressed in several segments of the renal tubule (medul-
or lipopolysaccharide (LPS). The cytokines tumor necro-lary thick ascending limb, proximal and distal convoluted
sis factor- (TNF-) and interleukin-1 (IL-1) have beentubule) as well as in the glomerulus, interlobular and
shown to stimulate iNOS gene expression by activatingarcuate arteries of the normal rat kidney [1]. Under
the transcription factor nuclear factor-B (NF-B), whilepathophysiological circumstances iNOS is up-regulated,
cytokine-mix uses AP-1 (activator protein-1) sites [13].in resident (glomerular mesangial and epithelial, smooth
We recently used NF-B decoy oligonucleotides to dem-muscle, and tubular cells) [2, 3], and even more so in
onstrate that the initial inflammatory response in the re-invasive inflammatory (glomerular and interstitial) cells
nal allograft, which includes vascular cellular adhesion[4]. Multiple distinct forms of iNOS have been found in
molecule (VCAM) expression and macrophage influx,the rat kidney, such as macrophage NOS, vascular
is NF-B–dependent [14]. Thus, it is quite likely thatsmooth muscle cell (VSMC) NOS [5], as well as an un-
up-regulation of iNOS in this model is a down-streamusual isoform [6].
inflammatory event. It is well-known that NF-B is acti-
vated by radical oxygen species [15]. Oxygen radicals
INDUCIBLE NOS IN RENAL DISEASE can be formed in the kidney both by inflammatory and
Although inflammation is the best-characterized stim- non-inflammatory cells [16–18]. Another possibility is
ulus of iNOS expression, in the kidney several other that iNOS itself is the source of O2 (see below). In these
pathophysiological settings have been identified in which situations iNOS would be a deleterious enzyme.
NO production by iNOS appears to play an important Graft rejection in allogenic cardiac transplantation was
role. In experimental cirrhosis, iNOS expression is in- reduced after seven days in iNOS-knockout mice with
creased in glomeruli [7], and aspecific NOS inhibition a reduction in infiltrating mononuclear cells [19]. In a
corrects arterial vasodilation, and improves volume ho- model of acute rejection in allogenic renal transplanta-
tion (Brown Norway to Lewis), we found improved renal
hemodynamics after specific iNOS inhibition for sevenKey words: nitric oxide, inducible NO synthase, kidney, cardiovascular
disease. days with iminoethyl-lysine (L-NIL) [20] and even bet-
ter protection with 7-butylhexahydro-1H-azepin-2-imine- 2002 by the International Society of Nephrology
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Fig. 1. (A) Allograft treated with low-dose cyclosporine A (2.5 mg/kg/day), with normal arteriole and glomerulus, but severely injury and vacuolated
tubules, with perivascular mononuclear cell infiltrate in edematous areas. (B) Allograft treated with low-dose cyclosporine A plus iminoethyl-
lysine, without vascular, glomerular and tubular damage. There is a slight rim of mononuclear cells around the tubules that is much less than in
panel A. (C ) Allograft treated with low-dose cyclosporine A plus butylhexahydro-azepin-imine, without vascular, glomerular and tubular damage
and only slight tubular lesions (A, B, and C, PAS-staining; 100) (printed with permission from [21]).
monohydrochloride (BAI; Fig. 1) [21]. These agents also well be dependent on the oxidative status of the micro-
environment.reduced tubulointerstitial macrophage influx and injury,
clearly supporting the concept of a deleterious role of
iNOS derived from inflammatory cells in allograft rejec- iNOS ACTIVITY DEPENDS ON
tion. Importantly, a specific NOS inhibition with NG- THE MICROENVIRONMENT
nitro-l-arginine methyl ester (L-NAME) is known to
As is the case for the other NOS isoforms, catalyticallyaccelerate renal injury in this model [22]. These observa-
active iNOS is a homodimer of hemoprotein. The iNOStions lead to two important conclusions concerning acute
reductase domain contains binding sites for the redoxtransplant nephropathy in particular and possibly renal
co-factors nicotinamide adenine dinucleotide phosphateinflammation in general: (1) the deleterious effects of
(NADPH), flavin mononucleotide (FMN), flavin adeno-
the large amounts of NO produced by iNOS in invasive
sine dinucleotide (FAD), and calmodulin (CaM). Two re-
cells are more important than the potentially beneficial ducing equivalents are transferred from NADPH via FMN
effects of NO produced by iNOS in resident cells; and (2) and FAD, to the oxidase domain under the control of
when aspecific NOS inhibition is applied in this setting, the Ca2/CaM complex. The oxidation of l-arginine then
detrimental effects of loss of NO production from consti- occurs in the cysteinyl thiolate-ligated heme group in
tutive NOS (eNOS and bNOS) outweigh the beneficial the presence of the co-factor tetrahydrobiopterin (BH4).
effects of iNOS inhibition. Three factors may be of critical importance in the actual
In chronic renal allograft rejection in rodents, iNOS reaction product of the iNOS enzyme: BH4, l-arginine and
gene expression was increased in concert with other in- antioxidant status.
flammatory mediators in the renal cortex [23]. However, Transfection of a human monocyte cell line expressing
beneficial effects of parenchymal iNOS expression have retroviral human iNOS results in iNOS mRNA and
been observed in chronic allogenic aortic and cardiac iNOS protein expression, but no nitric oxide release [26].
transplantation [19, 24, 25]. Thus, while in chronic vascu- NO synthesis in this cell line appeared strictly dependent
lar allograft rejection (and in chronic hypertension, see on exogenous BH4. Others and we have shown that re-
earlier in this article) NO production by iNOS can be combinant BH4-free iNOS produces O2 instead of NO
up-regulated as a compensatory mechanism, in acute (Huisman et al, unpublished observations) [27]. In con-
allograft rejection iNOS expression associated with infil- trast to previous observations in eNOS, superoxide pro-
trating inflammatory cells appears to be deleterious. duction by iNOS derives from both the reductase and
the heme domain. Addition/repletion of the enzyme withSuch differences in the effects of iNOS expression may
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BH4 can couple NADPH reduction to l-arginine oxida- ter transplantation, in other words, well after the phase
of ischemia-reperfusion. These observations suggest thattion in the reactive heme center but does not reduce
O2 release from the reductase domain. BH4 supplemen- in this phase the intrarenal availability of BH4 was not
a limiting factor. However, it should be pointed out thattation thus induces a shift from O2 production by BH4-
free iNOS to simultaneous NO and O2 production by besides enhancing NO synthesis, there are several other
pathways through which l-arginine could influence func-the BH4-repleted enzyme. Since O2 rapidly reacts with
NO to form the potent oxidant peroxynitrite in a diffu- tion and morphology of the (transplanted) kidney [35].
Beneficial effects include modulation of nitric oxidesion limited reaction with a rate constant of 6.7  109 
1.9  1010 [(mol/L) · s1] [28], one should address the production, conversion into agmatine [36], or stimula-
important question whether NO is ever solely released tion of glucagon secretion [37]. Detrimental effects in-
from iNOS, or whether iNOS should be considered as a clude conversion to citrulline and NO under influence
peroxynitrite (NO plus O2 ) producing enzyme. Most likely of iNOS, and enhancing effects, via l-ornithine formation,
NO bioavailability is critically dependent on sufficient on proliferation and collagen formation [38]. However,
antioxidant capacity of the microenvironment. When an- our observations in the allogeneic transplant model dem-
tioxidant status of the microenvironment is insufficient onstrate that in the early phase beneficial effects of
to prevent the reaction of O2 and NO released from the l-arginine supplementation clearly outweigh the puta-
enzyme, peroxynitrite formation will occur. This may tive detrimental effects. Moreover, in renal transplant
help explain why sometimes iNOS induction in the kid- recipients who are highly predisposed to cardiovascular
ney is beneficial, such as in hypertension, while in other diseases [39], the beneficial effects of l-arginine also may
situations such as allograft rejection with extensive oxy- manifest for a number of risk factors [40].
gen radical stress due to ischemia-reperfusion and inflam- Whether l-arginine also conveys protection against
mation, iNOS acts as a deleterious enzyme. Evidence of chronic allograft nephropathy remains to be determined.
iNOS “dysfunction” and subsequent peroxynitrite pro- In conclusion, recent data have shown iNOS can act
duction in allograft rejection is the enhanced expression as a superoxide, a peroxynitrite, as well as a nitric oxide-
of nitrotyrosine in proximal tubular epithelium of re- producing enzyme, while the biological effects of iNOS
jecting human renal allograft [29], and in proximal tu- probably depend upon the type of radical species re-
bules and invasive cells in our experimental studies [21]. leased by the enzyme as well as the antioxidant capacity
Furthermore, significant reduction of nitrotyrosine stain- of the cellular microenvironment of the enzyme. Modu-
ing after iNOS inhibition was also observed in our model. lation of this microenvironment may modulate the func-
To test the effect of BH4 on the balance between nitric tion of iNOS and thus could be used to reduce acute
oxide and O2 production in an inflammatory iNOS model, rejection in the kidney.
we performed transplantation experiments with addi-
Reprint requests to Ton J. Rabelink, M.D., Ph.D., Department oftional administration of the BH4-precursor sepiapterin. Vascular Medicine, University Medical Center, Utrecht, F02-126, Heidel-
Consistent with a modulating effect of BH4 on iNOS berglaan 100, 3584 CX Utrecht, The Netherlands.
E-mail: t.rabelink@digd.azu.nlfunction, sepiapterin could reduce O2 production and
vascular injury in the rejecting kidney (Vos et al, unpub-
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